DAX25.262 +0,5%Est505.997 +1,6%MSCI World4.343 -0,1%Top 10 Crypto12,04 -1,2%Nas23.671 +0,8%Bitcoin77.657 -0,2%Euro1,1641 ±0,0%Öl63,34 +1,0%Gold4.510 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Novo Nordisk A3EU6F Bayer BAY001 Deutsche Telekom 555750 DroneShield A2DMAA Allianz 840400 Amazon 906866 RENK RENK73 Siemens Energy ENER6Y BASF BASF11 Lufthansa 823212 Volkswagen (VW) vz. 766403 TUI TUAG50 Infineon 623100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen gehen stärker ins Wochenende -- DAX schließt nach Rekord höher -- Tilray übertrifft Erwartungen -- TUI, Alphabet, BMW, BioNTech, Rheinmetall, DroneShield, Rio Tinto, Merck & Co. im Fokus
Top News
Bilanzierungsfehler könnte Tech-Aktien belasten - Jim Chanos warnt vor Gefahr für NVIDIA-Partner Bilanzierungsfehler könnte Tech-Aktien belasten - Jim Chanos warnt vor Gefahr für NVIDIA-Partner
Top-News der Woche: Diese Themen waren diese Woche wichtig Top-News der Woche: Diese Themen waren diese Woche wichtig
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Immunic Aktie

Kaufen
Verkaufen
Immunic Aktien-Sparplan
0,5740 EUR +0,0060 EUR +1,06 %
BMN
0,6691 USD +0,0098 USD +1,49 %
nachbörslich
BTT
Immunic jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.68,48 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PHD4

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4525EP1011

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIMUX

Immunic Aktien News

DatumMeistgelesen
PR NewswireImmunic Highlights 2024 Accomplishments and Upcoming Milestones
EQS GroupEQS-News: Immunic, Inc. to Participate in Investor Conference in December
PR NewswireImmunic, Inc. to Participate in Investor Conference in December
EQS GroupEQS-News: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
PR NewswireImmunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
EQS GroupEQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
EQS GroupEQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
PR NewswireImmunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
EQS GroupEQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in November
PR NewswireImmunic to Participate in Industry, Scientific and Investor Conferences in November
EQS GroupEQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
PR NewswireImmunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
EQS GroupEQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
PR NewswireImmunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
EQS GroupEQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
PR NewswireImmunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
EQS GroupEQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
PR NewswireImmunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
EQS GroupEQS-News: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
EQS GroupEQS-News: Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
PR NewswireImmunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
EQS GroupEQS-News: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
PR NewswireImmunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
PR NewswireImmunic Appoints Jason Tardio as Chief Operating Officer and President
PR NewswireImmunic to Participate in Industry and Scientific Conferences in June
PR NewswireImmunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireImmunic to Participate in Investor and Scientific Conferences in May
PR NewswireImmunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
PR NewswireImmunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunolog...
PR NewswireImmunic to Host MS R&D Day and Participate in Investor Conferences in April
PR NewswireImmunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
PR NewswireImmunic to Participate in Investor and Scientific Conferences in March
PR NewswireImmunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
PR NewswireImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
PR NewswireImmunic to Participate in Investor and Scientific Conferences in February
PR NewswireImmunic Highlights 2023 Accomplishments and Upcoming Milestones
PR NewswireImmunic, Inc. Announces Private Placement of up to $240 Million

Immunic News

Immunic News: auf dieser Seite finden Sie alle Immunic News und Nachrichten zur Immunic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immunic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immunic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.